Latest Shareholder Approvals News

Jindalee Lithium has successfully raised $8 million through a private placement, complemented by a $1 million Share Purchase Plan, to advance its McDermitt Lithium Project and a strategic US SPAC transaction.

European Lithium Limited has launched a replacement options offer for holders of 205 million expiring options, with directors committing to fully participate and underwrite the offer pending shareholder approval at the upcoming AGM.

BCAL Diagnostics has launched a $10 million convertible note facility, with $5 million already committed, to strengthen its capital position and accelerate commercialisation of its cancer detection technologies.

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.

Australian Strategic Materials secures A$50.8 million via share placement to fund Korean plant expansion and advance US metals project, while navigating complex supply chain and funding risks.

ASM Limited has raised A$55 million to accelerate production capacity at its Korean Metals Plant and expand its footprint in the rare earths sector, responding to growing global demand and geopolitical supply chain pressures.

AdAlta Limited has raised up to A$1.1 million through a private placement, boosting its war chest to advance innovative cellular immunotherapy projects targeting solid cancers.

Radiopharm Theranostics has completed a A$35 million institutional placement and launched a A$5 million Share Purchase Plan, both at $0.03 per share, to fund drug manufacturing and clinical trials through 2027.

Resolution Minerals secures a $2 million placement from Tribeca Investment Partners, reinforcing its position in the U.S. critical minerals sector and advancing exploration at the strategically important Horse Heaven Project.

BCAL Diagnostics has established a $10 million convertible note facility, with $5 million already committed, to accelerate its cancer detection technologies and commercial milestones.

Veris Limited has acquired Melbourne-based Mesh Livable Communities and a 50% stake in the Parsel digital platform, boosting its urban planning and digital consulting capabilities. The deal, valued at up to AUD 3.18 million plus AUD 0.5 million for equity, is expected to be earnings accretive and strengthen Veris’ presence across Australia’s property and planning sectors.

Vectus Biosystems has agreed to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics for US$3 million in shares and warrants, gaining a strategic equity position while refocusing on its cardiovascular and fibrosis pipeline.